OBJECTIVE: To delineate the temporal patterns of outcome and to determine the probability of seizure freedom with successive antiepileptic drug regimens in newly diagnosed epilepsy. METHODS: Patients in whom epilepsy was diagnosed and the first antiepileptic drug prescribed between July 1, 1982, and April 1, 2006, were followed up until March 31, 2008. Outcomes were categorized into 4 patterns: (A) early and sustained seizure freedom; (B) delayed but sustained seizure freedom; (C) fluctuation between periods of seizure freedom and relapse; and (D) seizure freedom never attained. Probability of seizure freedom with successive drug regimens was compared. Seizure freedom was defined as no seizures for ≥1 year. RESULTS: A total of 1,098 patients were included (median age 32 years, range 9-93). At the last clinic visit, 749 (68%) patients were seizure-free, 678 (62%) on monotherapy. Outcome pattern A was observed in 408 (37%), pattern B in 246 (22%), pattern C in 172 (16%), and pattern D in 272 (25%) patients. There was a higher probability of seizure freedom in patients receiving 1 compared to 2 drug regimens, and 2 compared to 3 regimens (p < 0.001). The difference was greater among patients with symptomatic or cryptogenic than with idiopathic epilepsy. Less than 2% of patients became seizure-free on subsequent regimens but a few did so on their sixth or seventh regimen. CONCLUSIONS: Most patients with newly diagnosed epilepsy had a constant course which could usually be predicted early. The chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.
OBJECTIVE: To delineate the temporal patterns of outcome and to determine the probability of seizure freedom with successive antiepileptic drug regimens in newly diagnosed epilepsy. METHODS:Patients in whom epilepsy was diagnosed and the first antiepileptic drug prescribed between July 1, 1982, and April 1, 2006, were followed up until March 31, 2008. Outcomes were categorized into 4 patterns: (A) early and sustained seizure freedom; (B) delayed but sustained seizure freedom; (C) fluctuation between periods of seizure freedom and relapse; and (D) seizure freedom never attained. Probability of seizure freedom with successive drug regimens was compared. Seizure freedom was defined as no seizures for ≥1 year. RESULTS: A total of 1,098 patients were included (median age 32 years, range 9-93). At the last clinic visit, 749 (68%) patients were seizure-free, 678 (62%) on monotherapy. Outcome pattern A was observed in 408 (37%), pattern B in 246 (22%), pattern C in 172 (16%), and pattern D in 272 (25%) patients. There was a higher probability of seizure freedom in patients receiving 1 compared to 2 drug regimens, and 2 compared to 3 regimens (p < 0.001). The difference was greater among patients with symptomatic or cryptogenic than with idiopathic epilepsy. Less than 2% of patients became seizure-free on subsequent regimens but a few did so on their sixth or seventh regimen. CONCLUSIONS: Most patients with newly diagnosed epilepsy had a constant course which could usually be predicted early. The chance of seizure freedom declined with successive drug regimens, most markedly from the first to the third and among patients with localization-related epilepsies.
Authors: Brian C Callaghan; Kishlay Anand; Dale Hesdorffer; W Allen Hauser; Jacqueline A French Journal: Ann Neurol Date: 2007-10 Impact factor: 10.422
Authors: Robert S Fisher; Walter van Emde Boas; Warren Blume; Christian Elger; Pierre Genton; Phillip Lee; Jerome Engel Journal: Epilepsia Date: 2005-04 Impact factor: 5.864
Authors: Jerome Engel; Samuel Wiebe; Jacqueline French; Michael Sperling; Peter Williamson; Dennis Spencer; Robert Gumnit; Catherine Zahn; Edward Westbrook; Bruce Enos Journal: Epilepsia Date: 2003-06 Impact factor: 5.864
Authors: Vicente Villanueva; Mercedes Garcés; Elena López-Gomáriz; José María Serratosa; Beatriz González-Giráldez; Jaime Parra; Juan Rodríguez-Uranga; Manuel Toledo; Francisco Javier López González; Pedro Bermejo; Pau Giner; Ascensión Castillo; Albert Molins; Dulce Campos; José Ángel Mauri; Rosario Muñoz; Macarena Bonet; Pedro Serrano-Castro; Ana del Villar; Rosa Ana Saiz-Díaz Journal: Clin Drug Investig Date: 2015-02 Impact factor: 2.859
Authors: H L Grabenstatter; J Carlsen; Y H Raol; T Yang; D Hund; Y Cruz Del Angel; A M White; M I Gonzalez; F M Longo; S J Russek; A R Brooks-Kayal Journal: J Neurosci Res Date: 2014-05-07 Impact factor: 4.164